7389-14-2

Basic information

• Product Name: 5-Pyrimidinecarboxamide, 4-amino-2-methyl-
• Synonyms: 5-Pyrimidinecarboxamide, 4-amino-2-methyl-
• CAS NO: 7389-14-2
• Molecular Formula: C₆H₈N₄O
• Molecular Weight: 152.1539
• Mol File: 7389-14-2.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 340.6°Cat760mmHg
• Flash Point: 159.8°C
• Appearance: /
• Density: 1.344g/cm³
• Vapor Pressure: 8.5E-05mmHg at 25°C
• Refractive Index: 1.633
• CAS DataBase Reference: 5-Pyrimidinecarboxamide, 4-amino-2-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Pyrimidinecarboxamide, 4-amino-2-methyl-(7389-14-2)
• EPA Substance Registry System: 5-Pyrimidinecarboxamide, 4-amino-2-methyl-(7389-14-2)

Safety Data

• Hazardous Substances Data: 7389-14-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C6H8N4O/c1-3-9-2-4(6(8)11)5(7)10-3/h2H,1H3,(H2,8,11)(H2,7,9,10)

Upstream product

• 698-29-3 2-methyl-4-amino-5-cyanopyrimidine 
• 5472-46-8 ethyl 4-amino-2-methyl pyrimidine-5-carboxylate 
• 2134-36-3 ethyl 4-chloro-2-methylpyrimidine-5-carboxylate 
• 53135-24-3 ethyl 3,4-dihydro-4-oxo-2-methylpyrimidine-5-carboxylate 
• 14777-27-6 methyl acetimidate hydrochloride 
• 21689-52-1 aminomethylene cyanacetamide 

Downstream Products

• 120208-35-7 7-methylpyrimido[4,5-d]pyrimidin-4(3H)-one 
• 698-29-3 2-methyl-4-amino-5-cyanopyrimidine 
• 39209-56-8 2-methyl-7,9-dihydro-purin-8-one 
• 95-02-3 5-(aminomethyl)-2-methylpyrimidin-4-amine 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF PYRIMIDINE DERIVATIVES

A process for the preparation of 5-substituted 4-amino-2-methylpyrimidines of the formula (I) wherein R is CONH2 or CN, and of acid addition salts thereof, characterized in that a compound of formula H2N CH = C(R) CN (II) is reacted with acetimidic acid methyl ester or an acid addition salt thereof and that, if desired, a compound of formula (I) is transferred into an acid addition salt, and the transformation of a compound of formula (Il) wherein R is CONH2 into a compound of formula (Il) wherein R is CN by treatment with POCI3.